Publicado 4 números por año
ISSN Imprimir: 2155-014X
ISSN En Línea: 2155-0158
Endothelial Monocyte-Activating Polypeptide-II Improves Diastolic Heart Function and Vascular Relaxation in Type-I Diabetes Mellitus
SINOPSIS
To investigate the effects of endothelial monocyte-activating poly-peptide-II (EMAP II) on cardiac function and endothelium-dependent relaxation of aortic smooth muscles in streptozotocin-induced diabetes mellitus, experiments were conducted on 6-months-old male Wistar rats. In in vivo experiments, it has been shown that EMAP II improves diastolic function of the heart in streptozotocin-induced diabetic rats, which is evidenced by decreasing left ventricular end-diastolic pressure and end-diastolic myocardial stiffness by 13.8% and 26.3% (P < 0.05), respectively, compared to 25.4% (P < 0.05) and 25.5% (P < 0.05), respectively, in diabetic rats. EMAP II also decreases end-systolic pressure and arterial stiffness. In in vitro experiments on isolated aortic rings, it has been revealed that EMAP II improves endothelium-dependent relaxation of smooth muscles in strep-tozotocin-induced diabetic rats. An inhibition of NO-synthase (NOS) activity with L-NAME abolished EMAP Il-mediated vasodilatation in the endothelium-intact aortic rings, which indicates NOS-dependent mechanism of EMAP II action. Thus, EMAP II has a protective effect on the heart and vessels of rats with streptozotocin-induced diabetes. It improves diastolic heart function and restores vasorelaxation in diabetes mellitus.